Supaporn KaralakLertlak Leelaruangsang2011-02-222011-02-222010-03-242010-03-24Vajira Medical Journal; Vol. 49 No. 2 May - August 2005; 69-75http://imsear.searo.who.int/handle/123456789/132947Abstract Adverse effects of GPO-VIR to Blood Cells of the PLHA in the BMA General Hospital Supaporn           Karalak                             MD* Lertlak               Leelaruangsang              MD** *Blood Bank Department, BMA General Hospital **Out-patient Department, BMA General Hospital Objective: To determine the adverse effects of GPO-VIR (Drug combination of Stavudine, Lamivudine and Nevirapine) to blood cells of the patients living with HIV antigens (PLHA) in the BMA General Hospital. Study design: Descriptive study. Subjects: Fifty PLHA enrolled the Access To Care (ATC) project during May 2003-January 2004 , were treated with GPO-VIR in the out- patient clinic, Department of Medicine, BMA General Hospital. Methods: Sex, age, body weight, CD4 cell count and CBC (complete blood count) in the record of ATC project were collected and analyzed. Main outcome measures: Hematocrit, absolute neutrophil count (ANC), platelet count and CD4 cell count Results: After continuous treatment with GPO-VIR for one year, adverse effects to blood cells were not occurred in all subjects. Hematocrit, absolute neutrophil count and CD4 cell count were increased significantly. Conclusion: The adverse effects of GPO-VIR to blood cells (red blood cells, white blood cells and platelets) were not found in this study. The GPO-VIR was less bone marrow suppression. Hematocrit and absolute neutrophil count were increased significantly. Key words: GPO-VIR, Stavudine, Lamivudine, Nevirapine, bone marrow suppression. Vajira Med J 2005 ; 49 : 69 - 75en-USFaculty of Medicine, Vajira Hospital, University of Bangkok Metropolis, Bangkok, ThailandOriginal Articles